An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancerResearch in context

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancerResearch in context

Background: KRAS mutations are the most frequent oncogenic aberration in lung adenocarcinoma. KRAS mutant isoforms differentially shape tumour biology and influence drug responses. This heterogeneity challenges the development of effective therapies for patients with KRAS-driven non-small cell lung...

Full description

Bibliographic Details
Main Authors: Haiyun Wang, Qi Lv, Yue Xu, Zhaoqing Cai, Jie Zheng, Xiaojie Cheng, Yao Dai, Pasi A. Jänne, Chiara Ambrogio, Jens Köhler
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419306760

Internet

http://www.sciencedirect.com/science/article/pii/S2352396419306760

Similar Items